In a surprising move, the Supreme Court rejected a bid by a Bristol Myers Squibb unit to reinstate a $1.2 billion award it won in a contentious patent fight with a Gilead Sciences subsidiary over the lucrative market for gene therapies.
However, the decision came just days after the Supreme Court agreed to review a very similar case involving Amgen and two other drugmakers, which essentially involves the same issue, but comes at it from a different legal perspective.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
